| Joshua Ivare, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Joshua Ivare |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003519513 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 33652 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Ivare, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Joshua Ivare, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Mouse model studies show that administered genetically or topically, protein Smad7 protects against or heals mouth sores commonly associated with cancer treatment.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Placement of an endovascular stent has become a common procedure to successfully reopen blocked arteries. Even so, the treated vessel may once again narrow (restenosis), restricting blood flow. In the femoral and popliteal arteries in the leg, the use of nitinol stents magnifies this problem. About 20 to 40 percent of these stent patients experience restenosis 2 years after angioplasty. Now, an improved radiation technique may provide a safe and effective solution.
The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.
› Verified 5 days ago
Emily Leasure, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jorge A Velosa, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michael Ruediger Mueller, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mr. Karun Singh Badwal, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michal Reid, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Katherine Desprez Wick, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Dr. Allison Bock, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |